Return to content in this issue

Dupilumab as an Effective Therapy for Corticosteroid-Dependent/Resistant Type 2 Inflammation-Related Cutaneous Adverse Reactions

Shen Ch^1,2*, Wu N^1,2*, Liu Yang L^1,2, Wang B³, Liu T^1,2, Tao J<sup>1,2

1</sup>Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
²Hubei Engineering Research Center of Skin Disease Theranostics and Health, Wuhan, China.
³Department of Dermatology, University of Michigan, Ann Arbor, Michigan, United States.
*These two authors contribute equally to this work.

J Investig Allergol Clin Immunol 2024; Vol. 34(2)
doi: 10.18176/jiaci.0944

• Abstract
• Supplemental Materials

Key words: Drug rash, Corticosteroid-resistant, Dupilumab, Th2 pathway, DRESS syndrome

	Title	Type	Size
	doi10.18176_jiaci.0944_supplemental-materials-figures.pdf	pdf	407.63 Kb
	doi10.18176_jiaci.0944_supplemental-materials-table.pdf	pdf	228.85 Kb